Avaleht › Müeloom › Ohio › Cincinnati
Müeloom kliinilised uuringud linnas Cincinnati, OH
17 uuringut haiguse Müeloom jaoks otsivad osalejaid linnas Cincinnati ja selle ümbruses (umbes 30 miili raadiuses). Avage uuring, et näha, kes saab osaleda ja kuidas võtta ühendust uuringumeeskonnaga.
Ametlik uuringutekst (inglise keeles)
Otsite osalejaid uuringusse? Esitlege seda selle lehe tipus – $99 30 päeva eest →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
VärbamineFaas 3
- Research Site, Cincinnati
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
VärbamineFaas 3
- The Christ Hospital, Cincinnati
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
VärbamineFaas 3
- The Christ Hospital Cancer Center, Cincinnati
- Oncology Hematology Care, Cincinnati
- University of Cincinnati, Cincinnati
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
VärbamineFaas 2
- University of Cincinnati Medical Center, Cincinnati
- West Chester Hospital, West Chester · 15 mi kaugusel
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
VärbamineFaas 3
- University of Cincinnati Medical Center, Cincinnati
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
VärbamineFaas 2
- Oncology Hematology Care, Cincinnati
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
VärbamineFaas 3
- TriHealth Cancer and Blood Institute, Cincinnati
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
VärbamineFaas 3
- Oncology Hematology Care Clinical Trials, LLC, Cincinnati
- TriHealth Cancer Institute-Good Samaritan Hospital, Cincinnati
- Oncology Hematology Care Clinical Trials, LLC, Cincinnati
- ja veel 4
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
VärbamineFaas 3
- Good Samaritan Hospital - Cincinnati, Cincinnati
- Bethesda North Hospital, Cincinnati
- TriHealth Cancer Institute-Westside, Cincinnati
- ja veel 1
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
VärbamineFaas 3
- Research Site, Cincinnati
- Research Site, Montgomery · 11 mi kaugusel
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
VärbamineFaas 1/2
- Oncology Hematology Care - Blue Ash /ID# 272918, Cincinnati
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
VärbamineFaas 1
- University Of Cincinnati Medical Center /ID# 251746, Cincinnati
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
VärbamineFaas 3
- Good Samaritan Hospital - Cincinnati, Cincinnati
- Oncology Hematology Care Inc-Kenwood, Cincinnati
- Bethesda North Hospital, Cincinnati
- ja veel 2
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
VärbamineFaas 3
- University of Cincinnati, Cincinnati
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
VärbamineFaas 1
- Cincinnati Children's Hospital Medical Center, Cincinnati
- University of Cincinnati, Cincinnati
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
VärbamineFaas 2
- Oncology Hematology Care, Cincinnati
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
VärbamineFaas 1
- Oncology Hematology Care, Inc, Cincinnati
Müeloom uuringud teistes linnades
- New York City, NY60 uuringut
- Boston, MA42 uuringut
- Atlanta, GA41 uuringut
- Houston, TX38 uuringut
- Durham, NC37 uuringut
- Nashville, TN32 uuringut
- Denver, CO27 uuringut
- Rochester, MN24 uuringut
- St. Louis, MO24 uuringut
- Columbus, OH24 uuringut
- Baldwin Park, CA23 uuringut
- Chicago, IL22 uuringut
Muud uuringud linnas Cincinnati
- Mitteväikerakuline kopsuvähk35 uuringut
- Vähk (kõik liigid)27 uuringut
- Rinnavähk25 uuringut
- Südamepuudulikkus24 uuringut
- Käär- ja pärasoolevähk21 uuringut
- Äge müeloidne leukeemia20 uuringut
- Metastaatiline vähk20 uuringut
- Munasarjavähk19 uuringut
- Kopsuvähk19 uuringut
- Rasvumine19 uuringut
- Eesnäärmevähk18 uuringut
- Melanoom17 uuringut
Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.